Last reviewed · How we verify

Upfront therapy with oral spironolactone

Hasselt University · FDA-approved active Small molecule Quality 2/100

Upfront therapy with oral spironolactone is a Small molecule drug developed by Hasselt University. It is currently FDA-approved. Also known as: Aldactone.

At a glance

Generic nameUpfront therapy with oral spironolactone
Also known asAldactone
SponsorHasselt University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Upfront therapy with oral spironolactone

What is Upfront therapy with oral spironolactone?

Upfront therapy with oral spironolactone is a Small molecule drug developed by Hasselt University.

Who makes Upfront therapy with oral spironolactone?

Upfront therapy with oral spironolactone is developed and marketed by Hasselt University (see full Hasselt University pipeline at /company/hasselt-university).

Is Upfront therapy with oral spironolactone also known as anything else?

Upfront therapy with oral spironolactone is also known as Aldactone.

What development phase is Upfront therapy with oral spironolactone in?

Upfront therapy with oral spironolactone is FDA-approved (marketed).

Related